VANDA PHARMACEUTICALS INC. Operating Cash Flow
VANDA PHARMACEUTICALS INC. (VNDA) reported Operating Cash Flow of -$81.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$31.07M.
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$50.22M.
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$29.42M.
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$31.63M.
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) operating activities for fiscal 2025 was -$109.44M.
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) operating activities for fiscal 2024 was -$15.76M, a 223.09% decline from fiscal 2023.
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) operating activities for fiscal 2023 was $12.80M, a 59.98% decline from fiscal 2022.
- VANDA PHARMACEUTICALS INC. net cash provided by (used in) operating activities for fiscal 2022 was $31.98M, a 50.19% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$31.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$81.29M 10-Q · filed 2026-08-06 | -$110.70M derived: sum of 3 quarters · filed 2026-08-06 | -$142.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$50.22M 10-Q · filed 2026-05-07 | -$79.64M derived: sum of 2 quarters · filed 2026-05-07 | -$111.26M derived: sum of 3 quarters · filed 2026-05-07 | -$126.51M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$29.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$61.04M derived: sum of 2 quarters · filed 2026-02-12 | -$76.30M derived: sum of 3 quarters · filed 2026-08-06 | -$109.44M 10-K · filed 2026-02-12 |
| 2025-09-30 | -$31.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$46.88M derived: sum of 2 quarters · filed 2026-08-06 | -$80.03M 10-Q · filed 2025-10-30 | -$81.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$15.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$48.40M 10-Q · filed 2026-08-06 | -$50.22M derived: sum of 3 quarters · filed 2026-08-06 | -$64.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$33.15M 10-Q · filed 2026-05-07 | -$34.96M derived: sum of 2 quarters · filed 2026-05-07 | -$49.55M derived: sum of 3 quarters · filed 2026-05-07 | -$56.47M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$16.40M derived: sum of 2 quarters · filed 2026-02-12 | -$23.33M derived: sum of 3 quarters · filed 2026-02-12 | -$15.76M 10-K · filed 2026-02-12 |
| 2024-09-30 | -$14.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$21.51M derived: sum of 2 quarters · filed 2025-10-30 | -$13.94M 10-Q · filed 2025-10-30 | -$17.67M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | -$6.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $641.00K 10-Q · filed 2025-07-31 | -$3.09M derived: sum of 3 quarters · filed 2026-02-12 | -$5.14M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $7.57M 10-Q · filed 2025-05-08 | $3.84M derived: sum of 2 quarters · filed 2026-02-12 | $1.79M derived: sum of 3 quarters · filed 2026-02-12 | -$11.43M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | -$3.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$5.78M derived: sum of 2 quarters · filed 2026-02-12 | -$19.00M derived: sum of 3 quarters · filed 2026-02-12 | $12.80M 10-K · filed 2026-02-12 |
| 2023-09-30 | -$2.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$15.27M derived: sum of 2 quarters · filed 2024-11-07 | $16.53M 10-Q · filed 2024-11-07 | $25.95M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | -$13.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $18.58M 10-Q · filed 2024-08-01 | $28.00M derived: sum of 3 quarters · filed 2025-02-14 | $40.84M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | $31.80M 10-Q · filed 2024-05-09 | $41.22M derived: sum of 2 quarters · filed 2025-02-14 | $54.06M derived: sum of 3 quarters · filed 2025-02-14 | $59.74M derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | $9.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $22.25M derived: sum of 2 quarters · filed 2025-02-14 | $27.94M derived: sum of 3 quarters · filed 2025-02-14 | $31.98M 10-K · filed 2025-02-14 |
| 2022-09-30 | $12.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $18.52M derived: sum of 2 quarters · filed 2023-11-09 | $22.57M 10-Q · filed 2023-11-09 | $49.17M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-06-30 | $5.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-28 | $9.73M 10-Q · filed 2023-07-28 | $36.34M derived: sum of 3 quarters · filed 2024-02-08 | $45.73M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-03-31 | $4.05M 10-Q · filed 2023-05-03 | $30.65M derived: sum of 2 quarters · filed 2024-02-08 | $40.05M derived: sum of 3 quarters · filed 2024-02-08 | $59.07M derived: sum of 4 quarters · filed 2024-02-08 |
| 2021-12-31 | $26.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-08 | $36.00M derived: sum of 2 quarters · filed 2024-02-08 | $55.02M derived: sum of 3 quarters · filed 2024-02-08 | $64.21M 10-K · filed 2024-02-08 |
| 2021-09-30 | $9.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $28.41M derived: sum of 2 quarters · filed 2022-11-03 | $37.61M 10-Q · filed 2022-11-03 | $56.91M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-06-30 | $19.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $28.21M 10-Q · filed 2022-08-04 | $47.51M derived: sum of 3 quarters · filed 2023-02-09 | $56.89M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-03-31 | $9.19M 10-Q · filed 2022-05-06 | $28.50M derived: sum of 2 quarters · filed 2023-02-09 | $37.87M derived: sum of 3 quarters · filed 2023-02-09 | $61.88M derived: sum of 4 quarters · filed 2023-02-09 |
| 2020-12-31 | $19.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $28.68M derived: sum of 2 quarters · filed 2023-02-09 | $52.68M derived: sum of 3 quarters · filed 2023-02-09 | $51.77M 10-K · filed 2023-02-09 |
| 2020-09-30 | $9.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $33.38M derived: sum of 2 quarters · filed 2021-11-04 | $32.47M 10-Q · filed 2021-11-04 | $42.26M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $24.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $23.10M 10-Q · filed 2021-07-29 | $32.89M derived: sum of 3 quarters · filed 2022-02-24 | $38.89M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$907.00K 10-Q · filed 2021-05-06 | $8.88M derived: sum of 2 quarters · filed 2022-02-24 | $14.88M derived: sum of 3 quarters · filed 2022-02-24 | $35.40M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $9.79M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $15.79M derived: sum of 2 quarters · filed 2022-02-24 | $36.30M derived: sum of 3 quarters · filed 2022-02-24 | $45.95M 10-K · filed 2022-02-24 |
| 2019-09-30 | $6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $26.51M derived: sum of 2 quarters · filed 2020-10-29 | $36.16M 10-Q · filed 2020-10-29 | $51.42M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | $20.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $30.16M 10-Q · filed 2020-08-06 | $45.42M derived: sum of 3 quarters · filed 2021-02-11 | |
| 2019-03-31 | $9.64M 10-Q · filed 2020-05-07 | $24.91M derived: sum of 2 quarters · filed 2021-02-11 | ||
| 2018-12-31 | $15.26M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $29.99M 10-K · filed 2021-02-11 | ||
| 2018-09-30 | $14.72M 10-Q · filed 2019-11-07 | |||
| 2017-12-31 | -$1.98M 10-K · filed 2020-02-26 | |||
| 2014-03-31 | -$23.90M 10-Q · filed 2014-05-08 | -$36.06M derived: sum of 2 quarters · filed 2014-05-08 | -$46.33M derived: sum of 3 quarters · filed 2014-05-08 | -$54.37M derived: sum of 4 quarters · filed 2014-05-08 |
| 2013-12-31 | -$12.15M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | -$22.42M derived: sum of 2 quarters · filed 2014-02-25 | -$30.47M derived: sum of 3 quarters · filed 2014-02-25 | -$39.59M 10-K · filed 2014-02-25 |
| 2013-09-30 | -$10.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | -$18.31M derived: sum of 2 quarters · filed 2013-11-08 | -$27.44M 10-Q · filed 2013-11-08 | -$41.29M derived: sum of 4 quarters · filed 2014-05-08 |
| 2013-06-30 | -$8.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-31 | -$17.17M 10-Q · filed 2013-07-31 | -$31.02M derived: sum of 3 quarters · filed 2014-05-08 | -$41.18M derived: sum of 4 quarters · filed 2014-05-08 |
| 2013-03-31 | -$9.13M 10-Q · filed 2014-05-08 | -$22.97M derived: sum of 2 quarters · filed 2014-05-08 | -$33.14M derived: sum of 3 quarters · filed 2014-05-08 | -$45.35M derived: sum of 4 quarters · filed 2014-05-08 |
| 2012-12-31 | -$13.85M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | -$24.01M derived: sum of 2 quarters · filed 2014-02-25 | -$36.23M derived: sum of 3 quarters · filed 2014-02-25 | -$44.92M 10-K · filed 2014-02-25 |
| 2012-09-30 | -$10.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | -$22.38M derived: sum of 2 quarters · filed 2013-11-08 | -$31.07M 10-Q · filed 2013-11-08 | -$43.42M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-06-30 | -$12.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-31 | -$20.90M 10-Q · filed 2013-07-31 | -$33.26M derived: sum of 3 quarters · filed 2014-02-25 | -$40.43M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-03-31 | -$8.69M 10-Q · filed 2013-05-10 | -$21.05M derived: sum of 2 quarters · filed 2014-02-25 | -$28.22M derived: sum of 3 quarters · filed 2014-02-25 | -$33.84M derived: sum of 4 quarters · filed 2014-02-25 |
| 2011-12-31 | -$12.36M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | -$19.53M derived: sum of 2 quarters · filed 2014-02-25 | -$25.15M derived: sum of 3 quarters · filed 2014-02-25 | -$28.41M 10-K · filed 2014-02-25 |
| 2011-09-30 | -$7.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | -$12.79M derived: sum of 2 quarters · filed 2012-11-08 | -$16.05M 10-Q · filed 2012-11-08 | -$21.15M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | -$5.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | -$8.88M 10-Q · filed 2012-08-03 | -$13.98M derived: sum of 3 quarters · filed 2013-02-26 | -$19.05M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-03-31 | -$3.26M 10-Q · filed 2012-05-09 | -$8.36M derived: sum of 2 quarters · filed 2013-02-26 | -$13.43M derived: sum of 3 quarters · filed 2013-02-26 | |
| 2010-12-31 | -$5.10M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$10.17M derived: sum of 2 quarters · filed 2013-02-26 | -$10.90M 10-K · filed 2013-02-26 | |
| 2010-09-30 | -$5.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | -$5.80M 10-Q · filed 2011-11-07 | ||
| 2010-06-30 | -$728.00K 10-Q · filed 2011-08-05 | |||
| 2009-12-31 | $169.34M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |